CALGB 100801 (Alliance): A phase II multi-center study of the addition of azacitidine (AZA) following allogeneic transplantation using a targeted busulfan based conditioning regimen for high risk myelodysplasia (MDS) and older patients with acute myeloid leukemia (AML)   

Vij, Ravi ,  Hars, Vera ,  Blum, William ,  Shore, Tsiporah ... -  EBMT -  Bone Marrow Transplantation -  2015  

Abstract -  Primary Endpoint -  Primary Analysis -  Transplant -  CALGB-100801